<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE90CA04-1D62-4D88-B6C3-6C30EC90B31E"><gtr:id>AE90CA04-1D62-4D88-B6C3-6C30EC90B31E</gtr:id><gtr:name>VU University Medical Center</gtr:name><gtr:address><gtr:line1>VU University Medical Center</gtr:line1><gtr:line2>vd Boechorststraat 7</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D220695F-AA09-4E89-899B-89BB6AD3FFCA"><gtr:id>D220695F-AA09-4E89-899B-89BB6AD3FFCA</gtr:id><gtr:name>Imperial College School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection and Population Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE90CA04-1D62-4D88-B6C3-6C30EC90B31E"><gtr:id>AE90CA04-1D62-4D88-B6C3-6C30EC90B31E</gtr:id><gtr:name>VU University Medical Center</gtr:name><gtr:address><gtr:line1>VU University Medical Center</gtr:line1><gtr:line2>vd Boechorststraat 7</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D220695F-AA09-4E89-899B-89BB6AD3FFCA"><gtr:id>D220695F-AA09-4E89-899B-89BB6AD3FFCA</gtr:id><gtr:name>Imperial College School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/275BDF7A-7C42-40AE-A49E-FD1E2CD03215"><gtr:id>275BDF7A-7C42-40AE-A49E-FD1E2CD03215</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Sabin</gtr:surname><gtr:orcidId>0000-0001-5173-2760</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D1BE2EA-694D-41BA-8055-D1DB7D3D3658"><gtr:id>3D1BE2EA-694D-41BA-8055-D1DB7D3D3658</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Nicholas</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:orcidId>0000-0003-2384-4807</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4C48495-1923-4707-89F9-8E633268BD2A"><gtr:id>F4C48495-1923-4707-89F9-8E633268BD2A</gtr:id><gtr:firstName>Deenan</gtr:firstName><gtr:surname>Pillay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM004236%2F1"><gtr:id>BCE74522-D92A-4234-AC8D-3D4664BB5CAA</gtr:id><gtr:title>Continued follow-up of the United Kingdom Collaborative HIV Cohort (UK CHIC) and the UK HIV Drug Resistance Database (UK HDRD), 2014-2019</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M004236/1</gtr:grantReference><gtr:abstractText>The number of people living with the human immunodeficiency virus (HIV) in the UK continues to increase. Current treatment for HIV is very effective and, as a result, the life expectancy of a person living with HIV has increased substantially over the past 15 years. However, HIV remains extremely costly to the National Health Service and there are still many challenges that must be faced to ensure that people with HIV continue to live full and healthy lives. In particular, some people continue to experience side effects on treatment - these may be life-threatening, may lead to a reduction in quality-of-life, and may limit the drugs that patients can receive in the future. If patients are unable to take their treatment for periods of time, then virus may grow that is resistant to some of the currently available drugs. An increasing number of HIV-positive people are living to older age, which may also lead to an increase in the side effects that are seen as well as an increase in general age-related illness. In addition, many HIV-positive children are also surviving into adulthood - as yet, we have little information on the outcomes of this group as they switch their care to adult HIV clinics. A proportion of people with HIV in the UK are also infected with hepatitis C virus (HCV) which has implications for the timing and choice of treatments that can be used. Whilst HCV has traditionally been hard to treat in those who also have HIV, some of the newly available HCV drugs offer greater promise of a cure for HCV. However, a large-scale assessment of the use of these drugs in people also infected with HIV remains to be undertaken. There are therefore many questions that must be addressed to ensure that the outcomes of those living with HIV are optimised. In particular, although it is often said that people with HIV can expect to live a 'near-normal' lifespan, whether this will ultimately be possible is far from clear. In order to plan the need for health care services and to understand the need for new drugs, it is essential that any changes in the characteristics of the UK epidemic are monitored.
Since 2001, the UK Collaborative HIV Cohort (CHIC) Study has followed people with HIV in the UK, to monitor their use of treatments against HIV and their outcomes. The UK HIV Drug Resistance Database (UK HDRD) collects information on the results of any tests that are performed to determine whether the virus that infects these individuals has become resistant to any of the currently used treatments. The latest dataset includes data on &amp;gt;45,000 patients attending 16 clinics and is one of the largest such collaborations worldwide. This application is for continued support of the combined UK CHIC Study and UK HDRD until 2019 for the following reasons:

1. To study the outcomes of people with HIV in the UK, including a description of the drugs that are used and any resistance that may develop; 
2. To better understand of how HIV spreads between and within subgroups of the population; 
3. To assess whether new and infrequently encountered strains of HIV are likely to respond less well to treatment; 
4. To describe the use of new treatments for HCV in study participants, and to describe the success of these treatments, particularly in people who may get re-infected with HCV on multiple occasions;
5. To describe the outcomes of HIV-positive adolescents who switch their HIV care from paediatric to adult services and to model the likely problems that might result as the HIV population ages;
6. To explore the extent to which genetic factors might contribute to the outcomes of HIV and its treatment;
7. To investigate the potential effects of treatment, side effects and resistance on life expectancy in HIV-positive people.

A secondary aim is to continue to ensure that the UK plays a leading role in international HIV cohort research through the provision of high quality data to international studies.</gtr:abstractText><gtr:technicalSummary>Whilst current combination antiretroviral (cART) regimens for HIV are extremely effective, there are many questions that remain to be addressed to ensure the optimal outcomes of HIV-positive people. In order to plan the need for health care services and to understand the need for new drugs, it is essential that any changes in the characteristics of the UK epidemic are monitored. These changes may arise from the changing demographics of the HIV-positive population, an increase in viral diversity, the introduction of new drugs, generic forms of existing drugs and changing treatment paradigms (e.g. a move towards earlier initiation of cART), as well as increased use of cART drugs as part of pre- or post-exposure prophylaxis against HIV. Surveillance of clinical and resistance outcomes is therefore required to inform national treatment policies. The primary aim of this application is to continue to expand and maintain the combined UK CHIC and UK HDRD database in order to answer a wide-ranging spectrum of questions relating to the clinical outcomes of those with HIV in the UK. The secondary aim is to continue to ensure that the UK plays a leading role in international HIV cohort research through the provision of high quality data and scientific input to major collaborative studies. The proposed research will be conducted in an environment at University College London that provides expertise in surveillance and audit studies, surveys of sexual behaviour, randomised trials, qualitative methods, mathematical modelling, behavioural and basic science research. UCL provides access to information technology and bioinformatics capability through the Farr Institute, with UCL Platform Technologies providing biobanks and informatic support. This setting therefore provides an ideal environment in which to conduct large-scale HIV cohort studies, with opportunities to translate study findings into interventions for those living with HIV and for wider public health benefit.</gtr:technicalSummary><gtr:potentialImpactText>The primary non-academic beneficiaries of our research are those living with HIV in the UK, their treating physicians, and the National Health Service (NHS). Our findings will, however, also have relevance for such individuals in countries other than the UK. Whilst our clinical findings have greatest relevance for those in other resource-rich settings, our research around resistance and transmission of HIV will be of relevance to resource-limited settings, particularly as antiretroviral therapy is rolled out more widely. 

There are currently almost 100,000 people living with HIV in the UK. Despite the benefits of cART, it is estimated that the lifetime costs of HIV are &amp;pound;366,777. Thus, HIV continues to place a significant burden on the NHS. Even when treated, HIV is associated with a significant impact on quality of life (Duracinsky M, JAIDS, 2012). The Terence Higgins Trust/Age UK 50-Plus study (tht.org.uk) found that compared with their HIV-negative peers, HIV-positive people aged over 50 reported twice as many (non-HIV) long-term health conditions, had mobility problems and difficulties with everyday tasks, were less economically active, were less likely to have a financial cushion for old age and were more reliant on benefits. Any findings that result in further improvements in the way that people living with HIV are cared for, will likely result in substantial benefits to this population in the UK as well as their ability to remain in full-time employment, resulting in economic benefits for the country as a whole. The HIV patient community may additionally benefit through the increased capacity for work that may result.

The planning of health care services and antiretroviral drug prescribing must also be based on evidence. Changes to the UK HIV epidemic may arise from the changing demographics of the HIV-positive population (particularly the ageing population), an increase in viral diversity, the introduction of new drugs and changing treatment paradgms (e.g. earlier initiation of cART), as well as increased use of cART drugs as part of pre- (PrEP) or post-exposure prophylaxis against HIV. Whilst many of the recently licensed antiretroviral drugs are vulnerable to resistance, there is limited information on acquired and transmitted resistance to these drugs. Although the availability of generic drugs provides a significant potential for cost savings, concerns that the use of such drugs may be associated with lower rates of cART adherence (and therefore higher rates of treatment failure and resistance development) must be addressed. In particular, the use of more expensive novel agents in place of generics must be justified based on evidence. The impact of earlier initiation of cART and the roll-out of PrEP on the incidence of transmitted drug resistance and transmission of HIV is unknown. Finally, large-scale datasets are required to guide the diagnostic implementation and use of next generation sequencing methods in clinical practice. The information that is provided by this study will have a huge impact, therefore, on national treatment and care policies for those living with HIV with obvious financial benefits to the NHS. Our studies of associations with genotype may also identify new potential therapeutic targets, and the identification of genetic markers for stratification of patient management. 
Our results also have implications for the wider population at risk of HIV infection. In particular, our research on HIV transmission dynamics and the extent of bridging between the MSM and heterosexual epidemics will provide important information for the development of interventions to prevent the transmission of HIV. Through the input to mathematical models, our results will be of use of public health professionals. These models have already been applied at an international level and have been used to inform global policy for ART programmes through work with WHO.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-10-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-10-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2125277</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>VU University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>The COBRA Study</gtr:description><gtr:id>7DD4150D-9895-4F75-9770-DAF94F958AF8</gtr:id><gtr:impact>One publication to date (listed in the form)</gtr:impact><gtr:outcomeId>58ad5702d80e67.25318875-2</gtr:outcomeId><gtr:partnerContribution>Neuroimaging, clinical medicine, biomarkers, immunology, virology, genetics, statistics, epidemiology</gtr:partnerContribution><gtr:piContribution>We provide the statistical support for the COBRA study, which also incorporates data from participants in the UK CHIC Study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College School of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The COBRA Study</gtr:description><gtr:id>E27BFF38-A2E5-4714-A0D6-E13723ACFFF8</gtr:id><gtr:impact>One publication to date (listed in the form)</gtr:impact><gtr:outcomeId>58ad5702d80e67.25318875-1</gtr:outcomeId><gtr:partnerContribution>Neuroimaging, clinical medicine, biomarkers, immunology, virology, genetics, statistics, epidemiology</gtr:partnerContribution><gtr:piContribution>We provide the statistical support for the COBRA study, which also incorporates data from participants in the UK CHIC Study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV-CAUSAL (Harvard University plus others)</gtr:description><gtr:id>F40C975B-3087-43E4-BAF1-4E11DC506E76</gtr:id><gtr:impact>Several publications in high impact journals, all are listed in appropriate section</gtr:impact><gtr:outcomeId>GSen8wEKTPn-1</gtr:outcomeId><gtr:piContribution>Intellectual input into study design and analysis; provision of datasets; writing manuscripts</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>UK HIV Drug Resistance Database</gtr:description><gtr:id>CAA4383C-9735-488F-B429-2C263B04D66B</gtr:id><gtr:impact>Publications as listed in section 2 and further grant funding (described above)</gtr:impact><gtr:outcomeId>6ACA6DA042E-1</gtr:outcomeId><gtr:partnerContribution>Through collaboration with this study we have successfully applied for a new five-year programme grant from the MRC (G0900274)</gtr:partnerContribution><gtr:piContribution>The studies have provided joint scientific leadership and have equally contributed to statistical analyses</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College School of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The POPPY Study</gtr:description><gtr:id>4293C2E2-9B91-4501-90B8-BD118A7E29CA</gtr:id><gtr:impact>To date, two publications (listed on the form) have arisen from this collaboration. The collaboration is multi-disciplinary including HIV clinicians, neuroimagers, biomarker analysts, epidemiologists and statisticians.</gtr:impact><gtr:outcomeId>58ad5623cdf1d4.63819097-1</gtr:outcomeId><gtr:partnerContribution>Clinical management, neuroimaging, biomarker studies, HIV medicine, sleep medicine</gtr:partnerContribution><gtr:piContribution>Data from the UK CHIC study feeds into the POPPY Study (a cohort of HIV and ageing in the UK). The POPPY study has received funding from several funders, including the NIH, the British HIV Association and pharmaceutical companies, with around &amp;pound;200,000 coming to UCL over the next 3 years.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>UK Community Advisory Board - development of community blog</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3FD4077A-6251-4F94-945C-554A208CCF92</gtr:id><gtr:impact>We have recently started to work with our community team to develop a blog that will be linked to the UK-CAB website to provide updates on the HIV cohort studies. This is still in its infancy, as our community representative has no had experience in this role before - but we hope that this will go live later in 2017.</gtr:impact><gtr:outcomeId>58c2f977b257f1.49548950</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>135D29AD-0E0F-456E-BB35-5AFA09475BB7</gtr:id><gtr:title>Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56d990ddd8def3.69683509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>430752A5-A95A-402F-8BF4-F91066FF91D2</gtr:id><gtr:title>Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538dc621cb901e80c1188bb06941ac87"><gtr:id>538dc621cb901e80c1188bb06941ac87</gtr:id><gtr:otherNames>De Luca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56d990dbd66835.84325650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77F1ACCB-6098-417C-A6F2-858ADCC26D91</gtr:id><gtr:title>Increased brain-predicted aging in treated HIV disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbebf80586faa8467e68a1f856e160b9"><gtr:id>fbebf80586faa8467e68a1f856e160b9</gtr:id><gtr:otherNames>Cole JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58c2f62ca4b115.51173312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F03BB03-B57B-42C2-8715-0EC8603623D1</gtr:id><gtr:title>Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d990dbadcf46.92678783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D96A5C33-DB69-4682-BDC4-69F0E32E55C3</gtr:id><gtr:title>Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a944b1be04e87.03431744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BA22B8E-8364-43B8-8839-18C984017A97</gtr:id><gtr:title>Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/474d5ce681ccda4783f40aaa1ea09d40"><gtr:id>474d5ce681ccda4783f40aaa1ea09d40</gtr:id><gtr:otherNames>Migrants Working Group on behalf of COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>58ac78e6b72135.10646071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23163159-64CB-4592-B2CC-7E5F498DA28C</gtr:id><gtr:title>Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4063af6dad22e62292f5b01da1f6d12d"><gtr:id>4063af6dad22e62292f5b01da1f6d12d</gtr:id><gtr:otherNames>Tostevin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58ac78e60bb599.05717283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55E52C96-786D-4F26-AAFA-12B900372AF3</gtr:id><gtr:title>Defining cognitive impairment in people-living-with-HIV: the POPPY study.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aa3b8147846f8c253b4ed84dd68d528"><gtr:id>6aa3b8147846f8c253b4ed84dd68d528</gtr:id><gtr:otherNames>De Francesco D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58c2f62cd97772.58382153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBFF689C-92C2-42A0-BA62-9C45D1670BF0</gtr:id><gtr:title>Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da495b2d953fc71dbe50eea5d52fbc28"><gtr:id>da495b2d953fc71dbe50eea5d52fbc28</gtr:id><gtr:otherNames>Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58ac78e43dc0d9.67514826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E164CA8B-CA5D-4FCB-9C9B-2F79FE0EFEFD</gtr:id><gtr:title>Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdf3ab5f03a740b1177010c21cac6f17"><gtr:id>fdf3ab5f03a740b1177010c21cac6f17</gtr:id><gtr:otherNames>Haddow L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a944b1a4c1b51.17870368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB433FDD-22A2-45B3-AA13-CA599C14200B</gtr:id><gtr:title>Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c926053cd3c7f247fa364994945f7609"><gtr:id>c926053cd3c7f247fa364994945f7609</gtr:id><gtr:otherNames>Booth JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>56d990dc23b1a4.33863097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C2D3249-A4A1-4E61-B83C-36D30A1675C6</gtr:id><gtr:title>Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e621749d05215f018b58573cd1667e8"><gtr:id>8e621749d05215f018b58573cd1667e8</gtr:id><gtr:otherNames>Chereau F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a944b1c7e5d40.77930899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB1B2884-4564-435E-A867-0DBD0C946DB5</gtr:id><gtr:title>Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a944b1a21e306.29449231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3E6778F-2D14-4320-9EE5-003D3143C9A2</gtr:id><gtr:title>Renal tubular disease in the era of combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d426d779c840a490da55f26dbb7b7238"><gtr:id>d426d779c840a490da55f26dbb7b7238</gtr:id><gtr:otherNames>Hamzah L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dd630825.33172556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97380E59-B1BE-4E15-A2CE-A05C0582EF5E</gtr:id><gtr:title>A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc08391f270e071c476c7cde6ea98b68"><gtr:id>fc08391f270e071c476c7cde6ea98b68</gtr:id><gtr:otherNames>Mourad R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dd8dbf94.95615596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97D878D7-BAF9-4428-BF0B-AA76564E67AA</gtr:id><gtr:title>Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d990de4a8521.31653297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98E78A5B-3481-4042-B9E2-13BA9DA86A33</gtr:id><gtr:title>Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80c33faecbe92022585361658739da77"><gtr:id>80c33faecbe92022585361658739da77</gtr:id><gtr:otherNames>Warren-Gash C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-8126</gtr:issn><gtr:outcomeId>58ac78e3132450.76724634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>482DC98F-9A3E-4929-93A6-915B8DD4B16C</gtr:id><gtr:title>Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a22cdedac4bd986c28181b428e1b1c2d"><gtr:id>a22cdedac4bd986c28181b428e1b1c2d</gtr:id><gtr:otherNames>Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58ac78e5d07c35.80478233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79812E00-9922-4AFE-BE79-9215274162F9</gtr:id><gtr:title>Hepatitis B, hepatitis C, and mortality among HIV-positive individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a4a95ddd298f28da17be0ed8ee69b3d"><gtr:id>8a4a95ddd298f28da17be0ed8ee69b3d</gtr:id><gtr:otherNames>Thornton AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a944b1aab2859.62790372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FB4C11E-0C46-4327-AF1E-45ECA2AC23E9</gtr:id><gtr:title>Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d426d779c840a490da55f26dbb7b7238"><gtr:id>d426d779c840a490da55f26dbb7b7238</gtr:id><gtr:otherNames>Hamzah L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>58ac78e27b5517.87988329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>716AC1B0-7BAF-4186-BEDD-A55BEE248021</gtr:id><gtr:title>Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458a0d62a0ced7438b175b0a426b3139"><gtr:id>458a0d62a0ced7438b175b0a426b3139</gtr:id><gtr:otherNames>Underwood J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c2f62d10e142.62687989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71574AA2-5B37-407A-BE04-65EB05E9F73C</gtr:id><gtr:title>An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2280b53b8ea89e614bf096b707df6238"><gtr:id>2280b53b8ea89e614bf096b707df6238</gtr:id><gtr:otherNames>Smit E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5a944b1c9ed4f4.17835494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D1478A3-4391-40AC-A44D-5784832CA40F</gtr:id><gtr:title>Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>5a944b1c41e8b0.79452516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48F58449-5EA6-44E7-8987-D666C9C1C0B7</gtr:id><gtr:title>The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>CMAJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20fdc530f0acf18f9aa6993e7cf09af6"><gtr:id>20fdc530f0acf18f9aa6993e7cf09af6</gtr:id><gtr:otherNames>Klein MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2291-0026</gtr:issn><gtr:outcomeId>56d990de90c767.97517722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B8C204C-6F49-42E0-B166-B31FF4B1D642</gtr:id><gtr:title>Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95ce060460afd7ecfb47de3afe705795"><gtr:id>95ce060460afd7ecfb47de3afe705795</gtr:id><gtr:otherNames>O'Connor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>5a944b1c0f0156.27301343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F56234DC-9C80-4E9C-B6E0-BF5E8432BAAC</gtr:id><gtr:title>The association between detected drug resistance mutations and CD4T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ee0191fadaa18fc24b6cf304cc55b06"><gtr:id>6ee0191fadaa18fc24b6cf304cc55b06</gtr:id><gtr:otherNames>Schultze A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5a944b1b77a7f8.71590890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA9D2202-75E2-42E3-B8CF-38BF317C2EB4</gtr:id><gtr:title>When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58ac78e639c6a8.77391290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B9F198A-9014-4A0D-9BF1-411F62E0E479</gtr:id><gtr:title>Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c80f3aef44abde16148ceba1e325c6cd"><gtr:id>c80f3aef44abde16148ceba1e325c6cd</gtr:id><gtr:otherNames>Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a944b1b1b5183.88645294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D15255D-237B-4935-A674-48C3CCFA1D5C</gtr:id><gtr:title>Comparison of cluster-based and source-attribution methods for estimating transmission risk using large HIV sequence databases.</gtr:title><gtr:parentPublicationTitle>Epidemics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b57c72e1c57c992c20628af6fb86748f"><gtr:id>b57c72e1c57c992c20628af6fb86748f</gtr:id><gtr:otherNames>Le Vu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1878-0067</gtr:issn><gtr:outcomeId>5a944b1d4a6752.61566889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D77FB632-48F6-4A9D-82E0-0D53213A480A</gtr:id><gtr:title>Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>58ac78e4b55825.78238070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5A60D6A-BE1D-4C26-B9EE-27E4D15461D7</gtr:id><gtr:title>Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2d5ac94974cfb9a4cd49c119ea70ed"><gtr:id>6d2d5ac94974cfb9a4cd49c119ea70ed</gtr:id><gtr:otherNames>Ngo-Giang-Huong N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58ac78e4167dd1.11825634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB7A45C-B75F-4B0A-BFF2-3FBFE16665F4</gtr:id><gtr:title>Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21753c19115a53fc66f6c862b5fa4c1a"><gtr:id>21753c19115a53fc66f6c862b5fa4c1a</gtr:id><gtr:otherNames>AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a944b1babfd52.50412988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A044EA22-1BDF-40FA-90A8-602B35573B9F</gtr:id><gtr:title>Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58ac78e5772001.23274073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1EFFEFF-B51D-4485-9B58-6CEC19EE4B28</gtr:id><gtr:title>Development and application of a new measure of engagement in out-patient HIV care.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/365192f3fdd9512e949582a17de15e1e"><gtr:id>365192f3fdd9512e949582a17de15e1e</gtr:id><gtr:otherNames>Howarth AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>585d39b4924c22.65699587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43126C71-135C-4A04-A35B-691B0DC5FB64</gtr:id><gtr:title>Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c364bb47d84d53cfc830c1a911aa5fdf"><gtr:id>c364bb47d84d53cfc830c1a911aa5fdf</gtr:id><gtr:otherNames>Mbisa JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d990de0a5695.78531014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E567A757-D10B-4562-974E-4F4AF6C006B6</gtr:id><gtr:title>A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372c212584ac2efb0a65f6beb91c0c0d"><gtr:id>372c212584ac2efb0a65f6beb91c0c0d</gtr:id><gtr:otherNames>Ragonnet-Cronin ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d681f3f95d6.06688653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>819F9AF5-49DA-4295-BDC0-3D9668742E45</gtr:id><gtr:title>Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a944b1a79d132.19131922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F7938D2-C53B-4CEB-8BFE-335077F7AA56</gtr:id><gtr:title>Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56d990dd02bf06.20524285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F46CD73A-F650-4E8E-8F03-80A84E80CB0A</gtr:id><gtr:title>Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56d990dc5c8876.29784227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC9B6846-6E66-415D-8D99-9CE5A8E03595</gtr:id><gtr:title>Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na&amp;iuml;ve patients.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1097e87ec24072923b7411737a790c9b"><gtr:id>1097e87ec24072923b7411737a790c9b</gtr:id><gtr:otherNames>Bouteloup V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58ac78e5a46ea1.24428512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F6DF8E5-1398-429A-8051-FD9793CA8C11</gtr:id><gtr:title>No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>58ac78e54fb735.02920735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BA609B4-3985-47E2-8DE8-B81C4BC58754</gtr:id><gtr:title>Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58ac78e2a80b96.09897673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A709F0A9-A148-464F-9D1B-CE64D5769ECE</gtr:id><gtr:title>Association between engagement in-care and mortality in HIV-positive persons.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4f4f0e21733962eec60068490aaae8"><gtr:id>8b4f4f0e21733962eec60068490aaae8</gtr:id><gtr:otherNames>Sabin CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58ac78e2d88290.22972156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9FAE22-6B67-4B21-8ABD-4DFFD2F40C13</gtr:id><gtr:title>Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d990ddb469e1.86372148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1028D621-8AED-4085-AF3C-0C4BF66F35EC</gtr:id><gtr:title>Benchmarked performance charts using principal components analysis to improve the effectiveness of feedback for audit data in HIV care.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b25083b25e3ddef49c34b7fca20fc52"><gtr:id>3b25083b25e3ddef49c34b7fca20fc52</gtr:id><gtr:otherNames>Michael S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>5a944b1b4515a7.12870735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE6D3FA3-4BCB-4F45-8145-E8DB698E9650</gtr:id><gtr:title>Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d559b450019.24417085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EAE49D4-8CE7-40FD-96F0-6B040AFF4C1B</gtr:id><gtr:title>Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e26fd1d275edccf846e4efd533484ad"><gtr:id>5e26fd1d275edccf846e4efd533484ad</gtr:id><gtr:otherNames>Ragonnet-Cronin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>58ac78e6efd8b3.37661180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AF61356-5B23-4E39-8892-0EC147A4E04D</gtr:id><gtr:title>Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.</gtr:title><gtr:parentPublicationTitle>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3354b898dc3fab8f4c151b37b015c5bf"><gtr:id>3354b898dc3fab8f4c151b37b015c5bf</gtr:id><gtr:otherNames>Late presenters working group in COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1025-496X</gtr:issn><gtr:outcomeId>58ac78e68e9066.13170026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E17517BB-6373-4194-A53D-B64D65CF1D5D</gtr:id><gtr:title>The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dc99ea88.69954376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>122B4E36-98D5-46EC-A467-7C658C0AB911</gtr:id><gtr:title>Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46f2d9ffe46edb4c77cc56e89bb86f5"><gtr:id>c46f2d9ffe46edb4c77cc56e89bb86f5</gtr:id><gtr:otherNames>TenoRes Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58ac78e66807a6.64352325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6208CC5-4D75-4976-8889-0E25BFDAA651</gtr:id><gtr:title>Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa1aa1eeab4c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89598F49-1F42-4132-B2F7-A22606DB4616</gtr:id><gtr:title>Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bfb2ddc92ef0b6513ffe6fc4a000031"><gtr:id>8bfb2ddc92ef0b6513ffe6fc4a000031</gtr:id><gtr:otherNames>IeDEA and COHERE Cohort Collaborations</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a944b19eacb57.53034634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B5D396C-B4EB-4668-9E19-3FC65C617419</gtr:id><gtr:title>HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/563fd32d33db3b363f5c403619e78b9d"><gtr:id>563fd32d33db3b363f5c403619e78b9d</gtr:id><gtr:otherNames>El Bouzidi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58ac78e33ee4e0.16350028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2801E79-6A72-4C33-8377-C4B7F3CDAB87</gtr:id><gtr:title>Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a944b1ad58009.86418901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86A34158-3A53-47C8-B4FD-14B9E8EFB771</gtr:id><gtr:title>Predicting virological decay in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0ae6e7a98bbd0f130691f9c6ce1e21"><gtr:id>5d0ae6e7a98bbd0f130691f9c6ce1e21</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d65df4b1b92.70089223</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M004236/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>